The Clinical Significance of IGF-I in Maternal Serum During Pregnancy in Type 1 Diabetes
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Insulin-like growth factors (IGFs) constitute a system of peptides that promote mitosis, growth, and organ development by both paracrine and endocrine pathways, their bioavailability being modulated by at least six specific IGF-binding proteins (IGFBP). In type 1 diabetic pregnancies IGF-I and -II in maternal serum are associated with birth weight and their action modulated by IGFBP-3 and phosphorylated isoforms of IGFBP-1. Pregnancy-associated plasma protein-A (PAPP-A), a proteolytic substance of IGFBPs, is probably a modulator in early diabetic pregnancy while human placental growth hormone (hPGH) regulates the effect of IGF-I in pregnancy of diabetic and non-diabetic pregnancies. IGF-I in maternal serum increases concomitantly with progression of diabetic retinopathy despite good glycemic control in pregnancy. The role of the new insulin analogues in improving this effect has yet to be established. Retinopathy in pregnancy is associated with an elevated level of fibroblast growth factor-2 (FGF-2) and highly-phosphorylated IGFBP-1, the latter further increasing the level of free IGF-I and FGF-2. Thus, the effect on development of retinopathy may be directly mediated by IGF-I or indirectly by a modifying effect of IGFBP-3 and phosphorylated isoforms of IGFBP-1 with FGF-2 as a mediator.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of the two available long-acting insulin analogs, detemir has a theoretical advantage over glargine during pregnancy because glargine's much higher affinity for the IGF-1 receptor (150) raises concerns about increased mitogenic activity (150–152).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [151]
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
Lawrence, J. B., Oxvig, C., Overgaard, M. T., Sottrup-Jensen, L., Gleich, G. J., Hays, L. G., Yates, J. R., & Conover, C. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3149 · Cited by 706
SUIKKARI, A.-M., KOIVISTO, V. A., RUTANEN, E.-M., YKI-JÄRVINEN, H., KARONEN, S.-L., & SEPPÄLÄ, M. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-66-2-266 · Cited by 483 · cited 1×
“On the fetal side of placenta, IGF-I and II are mainly regulated by the IGFBP-1, which is GH independent, binds IGF-I more reluctantly than IGFBP-3, and is influenced by insulin in diabetic and non-diabetic subjects [34].”
BackgroundThe Pregnant Diabetic and Her Newborn
Farquhar, J. W. (1977) · Archives of Disease in Childhood · doi:10.1136/adc.52.8.671 · Cited by 406
GIUDICE, L. C., FARRELL, E. M., PHAM, H., LAMSON, G., & ROSENFELD, R. G. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-4-806 · Cited by 361 · cited 3×
“Similar techniques were applied; however, the mixture of sampling time and unpaired measurements (89 women between week 6 and 42 [36], 15 women between gestational week 20 and 41 [37]) may have influenced the latter findings.”
BackgroundMethodHOSSENLOPP, P., SEGOVIA, B., LASSARRE, C., ROGHANI, M., BREDON, M., & BINOUX, M. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-4-797 · Cited by 340 · cited 2×
“Similar techniques were applied; however, the mixture of sampling time and unpaired measurements (89 women between week 6 and 42 [36], 15 women between gestational week 20 and 41 [37]) may have influenced the latter findings.”
BackgroundMethodInsulin-like Growth Factors: Studies in Diabetics with and without Retinopathy
Merimee, T. J., Zapf, J., & Froesch, E. R. (1983) · New England Journal of Medicine · doi:10.1056/nejm198309013090904 · Cited by 280 · cited 3×
“Mitosis and growth of the retina and vitreous is promoted by IGFs [39-41].”
Grant, M., Russell, B., Fitzgerald, C., & Merimee, T. J. (1986) · Diabetes · doi:10.2337/diab.35.4.416 · Cited by 268 · cited 3×
“Mitosis and growth of the retina and vitreous is promoted by IGFs [39-41].”
BackgroundResultMirlesse, V., Frankenne, F., Alsat, E., Poncelet, M., Hennen, G., & Evain-Brion, D. (1993) · Pediatric Research · doi:10.1203/00006450-199310000-00011 · Cited by 202 · cited 1×
“The birth weight appears to correlate well with hPGH and IGF-I and suggestive of hPGH regulation of IGF-I in diabetic as well as in non-diabetic pregnancy [23,30,32,33], consequently, a low level of hPGH is associated with low maternal IGF-I in pregnancies complicated by intrauterine growth restriction [23,30].”
BackgroundDIABETES, DIABETIC ANGIOPATHY, AND GROWTH HORMONE
Lundbæk, K., Jensen, V., STEEN OLSEN, T., Ørskov, H., JUEL CHRISTENSEN, N., Johansen, K., PRANGE HANSEN, Å., & Østerby, R. (1970) · The Lancet · doi:10.1016/s0140-6736(70)92706-6 · Cited by 201 · cited 1×
“Since it was shown that pituitary ablation could halt proliferative diabetic retinopathy accompanied by a manifold reduction of IGF-I, increased focus has been on the hormonal changes with growth stimulating potential, which accompanies pregnancy [38,39].”
Background
Cited by
Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline
Blumer, I., Hadar, E., Hadden, D. R., Jovanovič, L., Mestman, J. H., Murad, M. H., & Yogev, Y. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2465 · Cited by 561
Pregnancy-associated Retinal Diseases and Their Management
Errera, M., Kohly, R. P., & da Cruz, L. (2013) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.08.001 · Cited by 147
Grissa, O., Yessoufou, A., Mrisak, I., Hichami, A., Amoussou-Guénou, D., Grissa, A., Djrolo, F., Moutairou, K. A., Miled, A., Khaïri, H., et al. (2010) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-10-7 · Cited by 84
Hami, J., Shojae, F., Vafaee-Nezhad, S., Lotfi, N., Kheradmand, H., & Haghir, H. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.412 · Cited by 56
Mathiesen, E. R., Damm, P., Jovanovic, L., McCance, D. R., Thyregod, C., Jensen, A. B., & Hod, M. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1213 · Cited by 43
“pregnancies [47], although a small decrease in IGF-1”
Background
Metadata
- Authors
- Lauszus, F. F.
- Affiliations
- Regionshospitalet Herning (DK)
- Corresponding author
- Finn Friis Lauszus
- ORCID
- Finn Friis Lauszus
- Venue
- Current Diabetes Reviews
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2007-08-01
- Volume
- 3
- Issue
- 3
- Pages
- 194-197
- ISSN
- 1573-3998 (ISSN-L)
- OpenAlex
- W2116566960
- Cited by
- 19
- References
- 42
- Citations by year
- 2024: 1 · 2021: 1 · 2019: 1 · 2016: 2 · 2015: 1 · 2013: 2 · 2012: 4
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Diabetes Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
- Keywords
- insulin-like growth factor I, type 1 diabetes, diabetes in pregnancy, maternal serum, IGF binding proteins, IGFBP-3, PAPP-A, placental growth hormone, diabetic retinopathy, fibroblast growth factor 2, birth weight, insulin analogues
- MeSH terms
- Birth Weight, Diabetic Retinopathy, Female, Humans, Infant, Newborn, Insulin-Like Growth Factor I, Mothers, Pregnancy, Pregnancy in Diabetics, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Clinical Significance of IGF-I in Maternal Serum During Pregnancy in Type 1 Diabetes. https://app.cochat.ai/papers/10.2174/157339907781368922
- The paper
- Lauszus, F. F. (2007). The Clinical Significance of IGF-I in Maternal Serum During Pregnancy in Type 1 Diabetes. Current Diabetes Reviews. https://doi.org/10.2174/157339907781368922
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.